You are here: Industry Insights > Liver Disease

News List

NICE pushes Doptelet for pre-surgery liver disease treatment PharmaTimes
March 05, 2020
The National Institute for Health and Care Excellence (NICE) has published a new final draft guidance recommending Dova Pharmaceuticals’ Doptelet (avatrombopag) for thrombocytopenia - ...
First investigational drug therapy for liver disease NASH awaiting FDA approval worldpharmanews
December 09, 2019
Patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease and a leading cause for liver transplantation in the U.S., currently lack an approved drug therapy ...
Boehringer partners with Yuhan for liver disease drug pharmaceutical-technology
July 03, 2019
Boehringer Ingelheim has partnered with South Korea-based Yuhan for the development of a first-in-class compound to treat nonalcoholic steatohepatitis (NASH) and other related liver disorders.
‘Concerning’ levels of non-alcoholic fatty liver disease among young people pharmatimes
April 16, 2019
A new study has shown an alarmingly high prevalence of non-alcoholic fatty liver disease (NAFLD) amongst……
Gilead NASH drug fails late stage trial pharmaphorum
February 13, 2019
Gilead’s top late-stage drug selonsertib, for patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), has failed a phase 3 trial.
ChemomAb Doses First Patient in Phase 1b Clinical trial of CM-101 americanpharmaceuticalreview
January 11, 2019
ChemomAb announced dosing of the first patient in a Phase 1b repeated dose clinical trial with CM-101 in non-alcoholic fatty liver disease (NAFLD) patients....
Hepatitis C Screening Can Help Prevent Liver Disease drugs
January 04, 2019
Infection with the hepatitis C virus can cause liver disease and even liver cancer. But once found, the virus can be cured, so screening is vital for those at risk, health experts say.......
Pfizer and Novartis collaborate to find liver disease therapy pharmaphorum
December 19, 2018
Pfizer has joined forces with Novartis to bring together the therapies they have been working on independently, to treat non-alcoholic steatohepatitis (NASH).....
Novartis and Pfizer link to develop NASH combo therapy pharmatimes
November 01, 2018
Novartis and Pfizer have announced an agreement that aims to advance the treatment of non-alcoholic steatohepatitis (NASH), a form of liver disease...
Takeda partners with new biotech Ambys in liver disease pharmatimes
August 09, 2018
Takeda has entered into a $100 million partnership with newly-launched biotech Ambys Medicines to support its discovery and development of therapies for people with serious liver disease.

Previous page 1 2 3 Next page